Background: Hidradenitis suppurativa (HS) is a disease characterized by the development of painful, deep-seeded nodules and abscesses. Treatment guidelines include a combination of lifestyle, surgical, and medical interventions. Isotretinoin has not been included in the treatment guidelines due to the limited number of studies and conflicting reports of efficacy. Objectives: The purpose of this study is to evaluate the clinical response to isotretinoin in HS patients and to determine whether there is a particular patient population that may benefit more from this treatment. Methods: A retrospective chart review was conducted on all HS patients treated with isotretinoin within the years of 2014-2016. Sex, age, weight, history of acne, Hurley stage, and treatment dose and duration were extracted from patient charts. Results: Of the 25 patients included in the study, 32% (8/25) had no response, 32% (8/26) showed partial response, and 36% (9/25) demonstrated complete response to isotretinoin treatment. Complete response was seen only in Hurley stage I and II patients. Hurley III patients made up 50% of the non-responders. Those with any sort of treatment response were more likely to be female, younger, weigh less, and have a higher prevalence of acne compared to non-responders. Limitations: This is a retrospective chart review with a small sample size of 25 patients. Conclusions: Physicians should consider isotretinoin as a potential treatment for HS, as it may be beneficial in patients with mild and moderate disease and patients who are female, younger, weigh less, and have a personal history of acne.

Jemec GB: Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012;366:158-164.
Revuz J: Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009;23:985-998.
Esmann S, Jemec GB: Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol 2011;91:328-332.
Matusiak L, Bieniek A, Szepietowski JC: Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 2010;90:264-268.
Shavit E, Dreiher J, Freud T, Halevy S, Vinker S, Cohen AD: Psychiatric comorbidities in 3,207 patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2015;29:371-376.
Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J: Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007;56:621-623.
Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al: Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473-478.
der Werth JM, Williams HC: The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000;14:389-392.
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhasz I, et al: European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-644.
Gollnick HP, Bettoli V, Lambert J, Araviiskaia E, Binic I, Dessinioti C, et al: A consensus-based practical and daily guide for the treatment of acne patients. J Eur Acad Dermatol Venereol 2016;30:1480-1490.
Layton A: The use of isotretinoin in acne. Dermatoendocrinol 2009;1:162-169.
Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al: Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014;171:1434-1442.
Soria A, Canoui-Poitrine F, Wolkenstein P, Poli F, Gabison G, Pouget F, et al: Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: a retrospective study based on patients' outcome assessment. Dermatology 2009;218:134-135.
Norris JF, Cunliffe WJ: Failure of treatment of familial widespread hidradenitis suppurativa with isotretinoin. Clin Exp Dermatol 1986;11:579-583.
Dicken CH, Powell ST, Spear KL: Evaluation of isotretinoin treatment of hidradenitis suppurativa. J Am Acad Dermatol 1984;11:500-502.
Boer J, van Gemert MJ: Long-term results of isotretinoin in the treatment of 68 patients with hidradenitis suppurativa. J Am Acad Dermatol 1999;40:73-76.
Shalita AR, Cunningham WJ, Leyden JJ, Pochi PE, Strauss JS: Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol 1983;9:629-638.
Scheinfeld N: Hidradenitis suppurativa: a practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J 2013;19:1.
Nelson AM, Gilliland KL, Cong Z, Thiboutot DM: 13-cis retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006;126:2178-2189.
Nelson AM, Cong Z, Gilliland KL, Thiboutot DM: TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells. Br J Dermatol 2011;165:526-533.
Peck GL, Olsen TG, Butkus D, Pandya M, Arnaud-Battandier J, Gross EG, et al: Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982;6:735-745.
Monk BE: Fordyce spots responding to isotretinoin therapy. Br J Dermatol 1993;129:355.
Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, et al: Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012;132:2198-2205.
Pino-Lagos K, Benson MJ, Noelle RJ: Retinoic acid in the immune system. Ann NY Acad Sci 2008;1143:170-187.
Jones DH, Cunliffe WJ, King K: Hidradenitis suppurativa-lack of success with 13-cis-retinoic acid. Br J Dermatol 1982;107:252.
Plewig G, Nikolowski J, Wolff HH: Action of isotretinoin in acne rosacea and gram-negative folliculitis. J Am Acad Dermatol 1982;6:766-785.
Kromann CB, Ibler KS, Kristiansen VB, Jemec GB: The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 2014;94:553-557.
Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al: Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009;61:51-57.
Dhaked DR, Meena RS, Maheshwari A, Agarwal US, Purohit S: A randomized comparative trial of two low-dose oral isotretinoin regimens in moderate to severe acne vulgaris. Indian Dermatol Online J 2016;7:378-385.
Brown CF, Gallup DG, Brown VM: Hidradenitis suppurativa of the anogenital region: response to isotretinoin. Am J Obstet Gynecol 1988;158:12-15.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.